Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 2:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 3,408 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Inflammatory Clear all
Completed Phase 1 Interventional

TD-1473 for Active Ulcerative Colitis (UC)

NCT02818686
View directory record Official record
Conditions
Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe
Interventions
TD-1473, Placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
5
States / cities
Scottsdale, Arizona • Monroe, Louisiana • Hermitage, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2021 · Synced Oct 25, 2026, 2:40 AM EDT
Completed Not applicable Interventional

Thiamine, Vitamin C and Hydrocortisone in the Treatment of Septic Shock

NCT03540628
View directory record Official record
Conditions
Septic Shock
Interventions
Thiamine and Vitamin C
Dietary Supplement
Lead sponsor
Corewell Health South
Other
Eligibility
18 Years to 90 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Saint Joseph, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Oct 25, 2026, 2:40 AM EDT
Completed Phase 2 Interventional Results available

A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy

NCT04071366
View directory record Official record
Conditions
Cytokine Release Syndrome
Interventions
Itacitinib, Immune effector cell therapy, Placebo, Yescarta
Drug · Biological
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
10
States / cities
Miami, Florida • Tampa, Florida • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Oct 25, 2026, 2:40 AM EDT
Completed No phase listed Observational

VENUS: Septic Gene Expression Using SeptiCyte

NCT02127502
View directory record Official record
Conditions
Sepsis, Systemic Inflammatory Response Syndrome (SIRS)
Interventions
Not listed
Lead sponsor
Immunexpress
Industry
Eligibility
18 Years to 89 Years
Enrollment
379 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
6
States / cities
Atlanta, Georgia • Chicago, Illinois • Maywood, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2018 · Synced Oct 25, 2026, 2:40 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Study Comparing a Soybean Oil-Based With an Olive Oil-Based Lipid Emulsion in ICU Patients Requiring TPN

NCT00672854
View directory record Official record
Conditions
Parenteral Nutrition
Interventions
ClinOleic 20% Intravenous Emulsion, Intralipid, 20% Intravenous Emulsion
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Oct 25, 2026, 2:40 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Non-myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (NST) for Patients With Refractory Crohn's Disease

NCT01288053
View directory record Official record
Conditions
Crohn's Disease
Interventions
Allogeneic Stem Cell Therapy
Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 45 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Oct 25, 2026, 2:40 AM EDT
Completed Phase 1 Interventional Results available

Safety and Tolerability Of Allogeneic Mesenchymal Stromal Cells in Pediatric Inflammatory Bowel Disease

NCT02150551
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
Allogeneic bone marrow-derived mesenchymal stromal cells
Biological
Lead sponsor
Catherine Bollard
Other
Eligibility
12 Years to 22 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 6, 2024 · Synced Oct 25, 2026, 2:40 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Investigating Age-dependent Effects of Egg Intake on HDL and Immune Profiles

NCT06086795
View directory record Official record
Conditions
Lipoproteins, Inflammatory Response
Interventions
Whole eggs, Egg yolks, Egg whites
Other
Lead sponsor
University of Connecticut
Other
Eligibility
18 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Storrs, Connecticut
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 25, 2026, 2:40 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Endoscopic Ultrasound Determines Disease Activity in Crohn's Disease And Ulcerative Colitis

NCT03863886
View directory record Official record
Conditions
Crohn Disease, Ulcerative Colitis
Interventions
Endoscopic ultrasound catheter (UM-2R/3R, Olympus)
Procedure
Lead sponsor
Carilion Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 29, 2021 · Synced Oct 25, 2026, 2:40 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test

NCT05243641
View directory record Official record
Conditions
Metastatic Breast Cancer, Breast Cancer
Interventions
Neratinib, Capmatinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Oct 25, 2026, 2:40 AM EDT
Completed Phase 2 Interventional Results available

Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis

NCT02647866
View directory record Official record
Conditions
Ulcerative Colitis, Digestive System Diseases, Colitis, Ulcerative, Colitis, Gastrointestinal Diseases, Inflammatory Bowel Diseases, Intestinal Diseases, Colonic Diseases, Autoimmune Disease, Abdominal Pain
Interventions
KHK4083, Placebo
Drug
Lead sponsor
Kyowa Kirin, Inc.
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 26, 2024 · Synced Oct 25, 2026, 2:40 AM EDT
Completed Phase 3 Interventional

Evaluation of Topical 10% Metronidazole Ointment for the Treatment of Active Perianal Crohn's Disease

NCT00509639
View directory record Official record
Conditions
Crohn's Disease
Interventions
10% Metronidazole Ointment
Drug
Lead sponsor
S.L.A. Pharma AG
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 13, 2012 · Synced Oct 25, 2026, 2:40 AM EDT
Not listed Not applicable Interventional

Cellular & Biocellular Regenerative Therapy in Musculoskeletal Pain, Dysfunction,Degenerative or Inflammatory Disease

NCT03090672
View directory record Official record
Conditions
Osteoarthritis, Rheumatoid Nodule, Degenerative Joint Disease, Tendinopathy, Tendinosis, Back Pain
Interventions
Normal Saline, Tissue Stromal Vascular Fraction, Platelet Rich Plasma, Cellular Stromal Vascular Fraction
Drug · Procedure · Biological
Lead sponsor
Robert W Alexander, MD
Other
Eligibility
18 Years to 90 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
North Attleboro, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 25, 2026, 2:40 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Comparison of Treximet & Imitrex as They Affect the Levels of Inflammatory Markers When the Patient is Actively Having a Migraine Headache

NCT01916395
View directory record Official record
Conditions
Migraine
Interventions
sumatriptan and Treximet
Drug
Lead sponsor
Gary E. Ruoff, M.D.
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 5, 2013 · Synced Oct 25, 2026, 2:40 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Sustained Acoustic Medicine (SAM) for Symptomatic Treatment of Knee Pain Related to Osteoarthritis

NCT05882812
View directory record Official record
Conditions
Osteo Arthritis Knee, Arthritis
Interventions
Sustained Acoustic Device with 2.5% Diclofenac Patch, Sustained Acoustic Device with 0% Diclofenac Patch, 2.5% Diclofenac Patches
Device · Drug
Lead sponsor
ZetrOZ, Inc.
Industry
Eligibility
35 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
3
States / cities
Stamford, Connecticut • Trumbull, Connecticut • Dryden, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Oct 25, 2026, 2:40 AM EDT
Terminated No phase listed Observational

Tofacitinib Response in Ulcerative Colitis - a Real World Prospective Multi-center Study

NCT03772145
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 80 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Oct 25, 2026, 2:40 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors

NCT04126070
View directory record Official record
Conditions
Hormone Sensitive Prostate Cancer, Prostate Adenocarcinoma, Metastasis Prostate Adenocarcinoma
Interventions
Androgen Deprivation Therapy, Nivolumab, Docetaxel
Drug
Lead sponsor
Xiao X. Wei, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
6
States / cities
La Jolla, California • Tampa, Florida • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 25, 2026, 2:40 AM EDT
Recruiting Phase 4 Interventional

A Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically

NCT07654751
View directory record Official record
Conditions
Psoriasis, Colitis, Ulcerative, Crohn Disease, Arthritis, Psoriatic
Interventions
Breast Milk Sample Collection, Guselkumab
Procedure · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 25, 2026, 2:40 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Sirolimus for Autoimmune Disease of Blood Cells

NCT00392951
View directory record Official record
Conditions
Autoimmune Pancytopenia, Autoimmune Lymphoproliferative Syndrome (ALPS), Evans Syndrome, Idiopathic Thrombocytopenic Purpura, Anemia, Hemolytic, Autoimmune, Autoimmune Neutropenia, Lupus Erythematosus, Systemic, Inflammatory Bowel Disease, Rheumatoid Arthritis
Interventions
sirolimus
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
1 Year to 30 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Oct 25, 2026, 2:40 AM EDT
Completed Not applicable Interventional Results available

Depression, Obesity and Inflammatory Markers

NCT02765100
View directory record Official record
Conditions
Bipolar Disorder, Depression, Obesity
Interventions
Minocycline
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 99 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 1, 2020 · Synced Oct 25, 2026, 2:40 AM EDT
Completed No phase listed Observational

Correlation Salivary Cortisol and Free Serum Cortisol to Total Serum Cortisol in MICU Septic Shock

NCT00523198
View directory record Official record
Conditions
Septic Shock
Interventions
Not listed
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 4, 2014 · Synced Oct 25, 2026, 2:40 AM EDT
Recruiting Not applicable Interventional

Ketogenic and Carnivore (Lion) Diets for Inflammatory Bowel Disease and Rheumatoid Arthritis

NCT07524244
View directory record Official record
Conditions
Rheumatoid Arthritis (RA), Crohn's Disease (CD), Ulcerative Colitis (UC)
Interventions
Ketogenic diet, Carnivore (Lion) Diet
Behavioral
Lead sponsor
Fuller Research Foundation
Other
Eligibility
18 Years to 64 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 25, 2026, 2:40 AM EDT
Completed Phase 3 Interventional Results available

Long-term Safety and Efficacy Study of Adalimumab in Pediatric Subjects With Ulcerative Colitis

NCT02632175
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Adalimumab
Biological
Lead sponsor
AbbVie
Industry
Eligibility
4 Years to 17 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
4
States / cities
Orlando, Florida • Minneapolis, Minnesota • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 25, 2026, 2:40 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Vedolizumab Subcutaneously (SC) as Maintenance Therapy in Ulcerative Colitis

NCT02611830
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Vedolizumab 300 mg IV, Placebo IV, Vedolizumab 108 mg SC, Placebo SC
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
383 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
28
States / cities
Little Rock, Arkansas • Wheat Ridge, Colorado • Middletown, Connecticut + 25 more
Source: ClinicalTrials.gov public record
Updated May 25, 2022 · Synced Oct 25, 2026, 2:40 AM EDT